Clinical trial NCT00780663: Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Official title: A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Neuroendocrine Tumors
Carcinoid Tumor
Keywords: Neuroendocrine
Carcinoid
NET
MEN-1
Islet cell
Lead sponsor: Cylene Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2008-10-28
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 2, open-label, multicenter, efficacy and safety study of quarfloxin in patients with low or intermediate grade neuroendocrine cancer. The purpose of this study is to evaluate the rate of clinical benefit response to quarfloxin treatment including the reduction in secretory symptoms of flushing and/or diarrhea or the reduction quantifiable hormones or other biochemical tumor markers.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed low or intermediate grade neuroendocrine carcinoma including carcinoid and islet cell cancer. Patients with neuroendocrine tumors associated with MEN1 syndrome are eligible.
* Measureable disease by RECIST
* Unresectable or metastatic disease
* Secretory symptoms of diarrhea or flushing or both attributed to their carcinoid tumor and/or quantifiable hormones or other biochemical markers
* Males and females 18 years of age or older.
* Zero to two prior cytotoxic chemotherapy regimens.
* Patients may be receiving concomitant octreotide Sandostatin®
* Patients must have central IV access, or agree to the insertion of a central IV line.
* All previous cancer therapies, radiation, and surgery, must have been discontinued at least 21 days prior to the start of treatment.
* Acceptable liver function
* Acceptable renal function
* Acceptable hematologic status
* ECOG Performance Status ≤1.
* Anticipated survival of at least 6 months.
* Able to maintain a patient diary.
* For men and women of child-producing potential, use of effective contraceptive methods during the study and for one month after discontinuation of treatment.
* Ability to understand the requirements of the study, provide written informed consent and agree to abide by the study restrictions and return to the clinic for required assessments.

Exclusion Criteria:

* Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid or small cell carcinoma.
* Pregnant or nursing women.
* Severe chronic obstructive pulmonary disease with hypoxemia or an uncorrectable pulmonary compromise.
* Seizures not controlled by anticonvulsant therapy.
* Participation in any investigational drug study within 28 days before quarfloxin administration or currently receiving investigational therapy.
* Patients with a second malignancy requiring active treatment.
* Active symptomatic bacterial, fungal, or viral infection including active HIV or viral hepatitis.
* Prior treatment with quarfloxin.
* Clinically significant bleeding event within the last 3 months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis.
* Patients who have exhibited allergic reactions to a similar structural compound or formulation.
* Any illness or condition that in the opinion of the investigator may affect safety of treatment or evaluation of any of the study's endpoints.

Primary outcomes:
measure: Clinical benefit. Clinical benefit is defined as a reduction of secretory symptoms or reduction of quantifiable hormones or other biochemical tumor markers where concomitantly there is an absence of radiological evidence for tumor progression.
timeFrame: monthly for clinical benefit, every two months for tumor progression
Secondary outcomes:
measure: Evaluate response rate, duration of response and progression free survival per RECIST criteria and the plasma and whole blood levels of quarfloxin.
timeFrame: One year
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Birmingham Hematology and Oncology
state: Alabama
city: Denver
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Fort Collins
country: United States
facility: Front Range Cancer Specialists
state: Colorado
city: Ocala
country: United States
state: Florida
city: Las Cruces
country: United States
facility: Southern New Mexico Cancer Center
state: New Mexico
city: Amarillo
country: United States
facility: Texas Oncology
state: Texas
city: Dallas
country: United States
facility: Texas Oncology
state: Texas
city: El Paso
country: United States
facility: El Paso Cancer Treatment Center
state: Texas
city: Kerrville
country: United States
facility: Cancer Care Centers of South Texas
state: Texas
city: San Antonio
country: United States
facility: UT Health Science Center
state: Texas
city: Tyler
country: United States
facility: Tyler Cancer Center
state: Texas
city: Seattle
country: United States
facility: Virginia Mason Medical Center
state: Washington
city: Vancouver
country: United States
facility: Northwest Cancer Specialists
state: Washington
Study officials:
References: